Thomas Potgieter
About Thomas Potgieter
Thomas Potgieter is the SVP of Cell Therapy at Bristol Myers Squibb, with over 20 years of experience in the biopharmaceutical industry, focusing on cell therapy and bioprocess engineering.
Company
Thomas Potgieter is currently working at Bristol Myers Squibb in the United States. He holds the position of Senior Vice President (SVP) in Cell Therapy, where he focuses on advancing cell therapy to reach more patients and improve outcomes.
Title
Thomas Potgieter is the Senior Vice President (SVP) of Cell Therapy at Bristol Myers Squibb. His role involves leading efforts to advance cell therapy technologies and processes, shaping the approach to achieve better patient outcomes.
Education and Expertise
Thomas Potgieter earned his Ph.D. in Bioprocess Engineering from the University of Cape Town, where he studied from 1998 to 1999. He also holds a B.Sc in Chemical Engineering from the University of Pretoria, where he studied from 1994 to 1997. With over 20 years of experience in the biopharmaceutical industry, he has built a strong background in bioprocess engineering and cell therapy.
Background
Thomas Potgieter has extensive experience in the biopharmaceutical industry. He worked at Merck in various positions from 2006 to 2023, including Senior Investigator, Director, Executive Director, Associate Vice President, and Vice President. Before joining Merck, he was a Senior Scientist at GlycoFi from 2002 to 2006 and a Technology Manager at SA Bioproducts from 1999 to 2002.
Achievements
During his tenure at Merck, Thomas Potgieter played a key role in the development and commercialization of multiple biologics and vaccines. He has contributed significantly to advancements in cell therapy technologies and processes and has extensive experience in leading cross-functional teams and managing large-scale biopharmaceutical projects.